Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Efficacy of hydrocolloid dressing for hand-foot skin reaction: J-SUPPORT 1701 APRON trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeSince hand-foot skin reaction (HFSR) is a dose-limiting toxicity associated with certain multikinase inhibitors, prophylactic measures to manage this adverse effect require improvement. This study aimed to evaluate the efficacy of depressurization using hydrocolloid dressing by comparing the effects of adding hydrocolloid dressing to standard prophylactic moisturizing versus moisturizing alone.
methodsWe conducted a phase 3 randomized self-controlled study for patients with unresectable colorectal cancer, gastrointestinal stromal tumors, or hepatocellular carcinoma who planned to receive either regorafenib or sorafenib. The primary endpoint was an incidence of grade 2 or higher HFSR (soles of the feet only) assessed using NCI CTCAE v.4.0. HFSR grading was performed according to pre-determined criteria, comprising a blinded central review of photographs of the foot, pain intensity (numerical rating scale), and patient-assessed interference score.
resultsBetween January 2019 and January 2021, 50 patients were enrolled. 48/50 patients received regorafenib, and two received sorafenib. The incidence of grade 2 or higher HFSR was significantly lower in the hydrocolloid dressing group than in the control group (20% vs. 50%, p < 0.0001, 95% CI of risk difference: [-42.7%, -17.3%]). Time to grade 2 or higher HFSR was significantly longer in the hydrocolloid dressing group (hazard ratio 0.32, p = 0.0017). The incidence of moderate, severe, or very severe in patient-reported HFSR, assessed using PRO-CTCAE, was also lower in the hydrocolloid dressing group (10% vs. 32%, p = 0.0002).
conclusionsOur study showed that the prophylactic use of hydrocolloid dressing was effective for HFSR.
trial registrationJ-SUPPORT1701, registered in December 2018 with the University Hospital Medical Information Network (UMIN000034853).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.